Document Detail

Alveolar soft part sarcoma 'revisited': clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours.
MedLine Citation:
PMID:  22173238     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: : Alveolar soft part sarcoma accounts for 0.5-1.0% of soft tissue sarcomas in the United States. At our Hospital, it constitutes 1.8% of the newly diagnosed soft tissue sarcomas. Lately, TFE3 has been found to be a useful immunohistochemical marker for diagnosing this sarcoma.
METHODS: : We reviewed 47 cases of alveolar soft part sarcoma that were either treated at Tata Memorial Hospital, Mumbai, India, or were referred in consultation from various parts of India. TFE3 immunohistochemical staining was performed on 22 alveolar soft part sarcomas and on 21 other tumours.
RESULTS: : Unlike most other large series, 58% of patients were males and 40% were females. The ages ranged from 2 to 54 years (median 24 years). Tumours were located in the deep soft tissues of lower extremities (54%), upper extremities (13%), head and neck (11%), retroperitoneum (10%), chest wall (6%), pelvis (4%), and were positive for TFE3 (20/22, 91%), desmin (3/18, 16%), myoglobin (1/6, 17%) and smooth muscle actin (1/9, 11%). TFE3 was positive in tumour controls that comprised paragangliomas (3/4), translocation related renal cell carcinoma (1/1), adrenocortical carcinoma (1/3) and granular cell tumour (1/3). Treatment consisted of primary surgical excision, metastatectomy, chemotherapy and radiotherapy. Seven tumours (24%) recurred locally and 21 of 29 (72%) metastasised, mainly to the lungs. Follow-up information (5-108 months, median 27.5 months) was available for 22 patients. No patients died in the relatively short follow-up period.
CONCLUSIONS: : TFE3 is a useful immunohistochemical marker for diagnosis of an alveolar soft part sarcoma. Awareness of other tumours expressing TFE3 is vital. Alveolar soft part sarcoma has a high metastasis rate but relatively good short-term survival. Surgical excision with follow-up forms the present management.
Bharat Rekhi; Abhijeet Ingle; Manish Agarwal; Ajay Puri; Siddharth Laskar; Nirmala A Jambhekar
Related Documents :
21987288 - Lecture: fotemustine in brain tumors.
20595448 - Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line t...
9060528 - Phase ii study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal ca...
22158068 - Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process ...
7502418 - Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure.
21385918 - Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective st...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pathology     Volume:  44     ISSN:  1465-3931     ISO Abbreviation:  Pathology     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0175411     Medline TA:  Pathology     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-7     Citation Subset:  IM    
*Departments of Pathology †Surgical Oncology (Bone and Soft Tissues) ‡Radiation Oncology, Tata Memorial Hospital, Parel §Department of Orthopaedics, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple levels on LLETZ biopsies do not contribute to patient management.
Next Document:  Placental fetal vascular thrombosis lesions and maternal thrombophilia.